Metabolic HealthResearch PaperOpen Access

Scientists Identify Key Enzyme Driving Muscle Loss in COPD Patients

A novel TNF-α–p53–Prodh2–cGAS/STING axis links chronic lung inflammation to sarcopenia, revealing a promising therapeutic target.

Saturday, October 3, 2026 3 views
Published in Aging Cell
Cross-sectioned human thigh muscle tissue under microscope showing atrophied muscle fibers alongside a researcher in a white lab coat examining MRI scans of leg muscles

Summary

People with COPD often lose muscle mass and strength, and the inflammatory molecule TNF-α is known to be high in those who do. This study asked how TNF-α actually damages muscle. Researchers found that it switches on a mitochondrial enzyme called Prodh2 in muscle precursor cells, through the stress protein p53. More Prodh2 means more reactive oxygen molecules, which damage mitochondria and leak mitochondrial DNA into the cell. The cell reads that leaked DNA as a danger signal and activates the cGAS/STING immune pathway, leading to cell death, halted growth, and shrinkage. Blocking Prodh2 prevented these effects in cultured muscle cells. In mice with smoke-induced COPD and muscle atrophy, silencing Prodh2 in muscle reduced wasting and restored grip strength. This is early preclinical work, but it points to a possible new therapeutic target.

Detailed Summary

Sarcopenia, the progressive loss of muscle mass, strength, and function, affects roughly 32%–33% of people with chronic obstructive pulmonary disease (COPD), according to background literature cited in the article. It is associated with poorer exercise capacity, lower quality of life, and higher mortality. This study investigated how the inflammatory cytokine tumor necrosis factor-alpha (TNF-α) contributes to muscle dysfunction, focusing on mitochondrial stress in muscle progenitor cells called myoblasts.

The researchers combined human samples, mouse models, and cultured C2C12 myoblasts. They collected serum from 30 people: 10 healthy controls, 10 COPD patients without sarcopenia, and 10 COPD patients with sarcopenia. COPD and sarcopenia were assessed using GOLD and Asian Working Group for Sarcopenia criteria, respectively. Male C57BL/6J mice underwent 24 weeks of cigarette-smoke exposure, with hindlimb unloading during the final two weeks in the sarcopenia model. C2C12 cells received TNF-α at 0, 5, 10, or 20 ng/mL for 24–72 hours, depending on the experiment. RNA sequencing compared control and TNF-α-treated cells, with three samples per group.

The abstract reports that Prodh2, a mitochondrial metabolic enzyme, was significantly upregulated in sarcopenic COPD patients and the corresponding mouse model. In myoblasts, TNF-α induced Prodh2 transcription through a p53-dependent pathway. Increased Prodh2 triggered excessive mitochondrial reactive oxygen species and mitochondrial DNA release. Cytosolic mitochondrial DNA then activated the cGAS/STING innate immune pathway, leading to apoptosis, proliferation arrest, and atrophy. Prodh2 knockdown reversed these effects in vitro.

The mouse intervention lasted 12 weeks and included control AAV, AAV-shProdh2, a TNF-α neutralizing antibody, and combination-treatment groups. AAV was administered once into the gastrocnemius muscle at 1 × 10^11 viral genomes per mouse; the antibody was given at 10 mg/kg twice weekly. The abstract reports that muscle-specific Prodh2 knockdown ameliorated muscle atrophy and restored strength. The methods specify a forelimb grip-strength test, but the supplied excerpt does not provide numerical treatment effects or comparative results for the antibody and combination arms.

The study links chronic inflammation to muscle dysfunction through a TNF-α–p53–Prodh2–cGAS/STING pathway. The introduction identifies hydroxyproline degradation by Prodh2 as a source of mitochondrial reactive oxygen species. These findings make Prodh2 a candidate therapeutic target, but whether targeting it benefits age-related sarcopenia beyond COPD remains untested in the supplied text.

Important limitations include the small human sample, the observational nature of the human comparison, use of male mice only, and reliance on a cell line and local viral knockdown. No human therapeutic safety or efficacy results are reported in the supplied text. The excerpt ends during the methods, so detailed results, effect sizes, and statistical analyses cannot be verified beyond the abstract.

Key Findings

  • The study enrolled 30 people: 10 healthy controls, 10 COPD patients without sarcopenia, and 10 COPD patients with sarcopenia. The abstract reports significantly increased Prodh2 in sarcopenic COPD patients and the corresponding mouse model.
  • The sarcopenic COPD mouse model used male C57BL/6J mice exposed to cigarette smoke for 24 weeks, with hindlimb unloading during the final two weeks.
  • In myoblasts, TNF-α induced Prodh2 transcription through a p53-dependent pathway.
  • Prodh2 upregulation triggered excessive mitochondrial reactive oxygen species and mitochondrial DNA release; cytosolic mitochondrial DNA activated cGAS/STING signaling.
  • The abstract reports that Prodh2 knockdown reversed the resulting myoblast dysfunction, including apoptosis, proliferation arrest, and atrophy, in vitro.
  • Muscle-specific Prodh2 knockdown ameliorated muscle atrophy and restored strength in mice. The methods describe a single intramuscular AAV-shProdh2 dose of 1 × 10^11 viral genomes per mouse, a 12-week intervention, and forelimb grip-strength testing.
  • Anti-TNF-α and combination-treatment arms were included, but their outcomes and comparative efficacy are not reported in the supplied excerpt.

Methodology

The study combined human serum samples from three groups of 10 participants, male C57BL/6J mouse models, and C2C12 myoblast experiments. Human diagnoses used GOLD and AWGS criteria. The sarcopenic COPD model used 24 weeks of cigarette-smoke exposure with hindlimb unloading during the final two weeks. Cells received TNF-α at 0–20 ng/mL for 24–72 hours depending on the experiment; RNA sequencing compared control and TNF-α-treated cells with n=3 per group. Mouse intervention groups included AAV-shNC, AAV-shProdh2, anti-TNF-α, and combination treatment over 12 weeks. Described measurements include forelimb grip strength, gastrocnemius weight, muscle-fiber cross-sectional area, TUNEL apoptosis testing, and EdU proliferation testing. The abstract reports in vitro Prodh2 knockdown, but the excerpt does not specify its delivery method. The supplied text ends during the methods and does not include statistical-analysis procedures or detailed results.

Study Limitations

The human cohort was small (n=10 per group) and cross-sectional, only male mice were used, and C2C12 cells and local AAV knockdown may not translate to patients or to a systemically deliverable drug. COPD sarcopenia was modeled with smoke plus hindlimb unloading, which may not fully reflect human disease. Conflict-of-interest and author-stated limitation details were not included in the supplied text.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: